Our team and leaders have years of experience in global biopharma companies. Our PMs are trained scientists with PhD degree in the US and Europe.
We support flexible collaboration models that fit different projects to meet diversified customer needs. In projects with limited budget, upon request, we take on more roles throughout the project life cycle.
GenScript ProBio developed the distinguishing Phase-appropriate Compliance (PAC) quality system to meet worldwide stringent regulatory standards (including US-FDA/EU-EMA/China-NMPA), which will benefit our customers in a way of high quality, cost-effectiveness, efficiency and credibility.
Current capacity: up to 20 GCT IND and 400 L biologics.
Total 16,800 L bioreactors by 2023.
Initium Therapeutics Strategically collaborates with GenScript ProBioLearn More »
GenScript ProBio CEO Brain Min Interviewed by the Medicine Maker Learn More »
GenScript ProBio Chinese Brand Unveiled, CDMO Capacity Upgraded Learn More »
GenScript ProBio Wins Bioprocessing Excellence in CDMO Services from IMAPACLearn More »
GenScript ProBio is the bio-pharmaceutical CDMO segment of GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.
GenScript ProBio’s innovative solutions for antibody drug development include antibody drug discovery, antibody engineering and antibody characterization. In terms of biologics development service, GenScript ProBio has built a regulatory-compliant platform, from stable cell line development to clinical manufacturing services, providing high quality material for IND and clinical trials. GenScript ProBio’s total gene and cell therapy solution covers CMC of plasmid and virus for IND filing as well as clinical manufacturing and commercial manufacturing.
Toward the mission of “Innovation through Collaboration”, GenScript ProBio is committed to helping customers significantly lower R&D costs and building a healthier future.